Previous 10 | Next 10 |
Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q3 GAAP EPS of -$0.15 misses by $0.08 . Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M . As of September 30, 2022, Sol-Gel had $25.5 million in cash, cash equivalents and deposits, and $9.8 million in marketa...
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribers Sol-Gel’s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (N...
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today th...
Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q2 GAAP EPS of $0.01 beats by $0.11 . Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M . For further details see: Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M ...
P rescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel r eceives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”) for FDA approval o...
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced th...
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced tha...
Sol-Gel Technologies press release (NASDAQ:SLGL): Q1 GAAP EPS of -$0.18 beats by $0.11. As of March 31, 2022, Sol-Gel had $30.2 million in cash, cash equivalents and deposits, and $6.1 million in marketable securities for a total balance of $36.3 million. For further details see: Sol-Ge...
FDA approval for EPSOLAY ® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year ; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products ...
The Food and Drug Administration (FDA) approved Sol-Gel Technologies (NASDAQ:SLGL) Epsolay, a proprietary cream formulation of benzoyl peroxide 5%, to treat inflammatory lesions of rosacea in adults. The company said the benzoyl peroxide in Epsolay is encapsulated within silica-based patented...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...